ArticlePsychopharmacology2026
Intact neurophysiological markers of death denial in long-term ayahuasca users.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThere is growing enthusiasm around the potential of psychedelics to transform how individuals engage with the theme of death, with self-report evidence suggesting these substances foster acceptance and reduce fear-of-death. Yet, given extensive evidence linking unconscious processes to mortality avoidance, current research efforts remain limited and call for implicit and neurobiology-based measures. OBJECTIVES &
methodsTo this end, we applied a validated no-report magnetoencephalogram (MEG) visual MisMatch Response (vMMR) paradigm to assess whether long-term ayahuasca users (N = 50), compared to previously published data from healthy controls and experienced meditators, show self-specific neurophysiological markers of death-denial/acceptance. Self-report and behavioral measures of fear-of-death were also collected.
resultsCluster-based permutation analyses on the vMMR data showed that ayahuasca users' brains responded to the coupling of death and self-stimuli in a manner indicating denial rather than acceptance. At the same time, 1-way ANOVAs and post hoc t-tests analyses indicated that the ayahuasca group evidenced less implicit fear-of-death than the general population, and less explicit fear-of-death than both the general and meditator samples. Further correlation analyses on the neurophysiological ayahuasca sample death-denial marker supported its construct validity by associating it with less self-reported death acceptance and reduced accessibility to death-related thoughts. Finally, death-denial was linked to greater life satisfaction, supporting its adaptive role.
conclusionsThese findings provide preliminary evidence that while ayahuasca may alter how humans interact with the theme of death on conceptual and affective levels of cognitive processing, on automatic, perceptual unconscious levels of self-specific processing, death-denial processes appear to remain intact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.